APOL1: The Balance Imposed by Infection, Selection, and Kidney Disease

被引：28
作者：
Beckerman, Pazit [1 ,2 ,3 ]
Susztak, Katalin [1 ,2 ]
机构：
[1] Univ Penn, Perelman Sch Med, Dept Med, Renal Electrolyte & Hypertens Div, Philadelphia, PA 19104 USA
[2] Univ Penn, Perelman Sch Med, Dept Genet, Philadelphia, PA 19104 USA
[3] Sheba Med Ctr, Inst Nephrol & Hypertens, Tel Hashomer, Israel
来源：
TRENDS IN MOLECULAR MEDICINE | 2018年 / 24卷 / 08期
关键词：
TRYPANOSOME LYTIC FACTOR; STAGE RENAL-DISEASE; RESISTANCE-ASSOCIATED PROTEIN; LIPID-BINDING PROTEIN; RISK VARIANTS; APOLIPOPROTEIN L1; AFRICAN TRYPANOSOMES; FUNCTION DECLINE; INNATE IMMUNITY; GENE VARIANTS;
D O I：
10.1016/j.molmed.2018.05.008
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Chronic kidney disease (CKD) affects millions of people and constitutes a major health and financial burden worldwide. People of African descent are at an increased risk of developing kidney disease, which is mostly explained by two variants in the Apolipoprotein L1 (APOL1) gene that are found only in people of west African origin. It is hypothesized that these variants were genetically selected due to the protection they afford against African sleeping sickness, caused by the parasite Trypanosoma brucei. Targeting mutant APOL1 could have substantial therapeutic potential for treating kidney disease. In this review, we will describe the intriguing interplay between microbiology, genetics, and kidney disease as revealed in APOL1-associated kidney disease, discuss APOL1-induced cytotoxicity and its therapeutic implications.
引用
收藏
页码：682 / 695
页数：14
相关论文
共 50 条
  • [31] APOL1 and Proteinuria in the AASK Unraveling the Pathobiology of APOL1
    O'Toole, John F.
    Bruggeman, Leslie A.
    Sedor, John R.
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2017, 12 (11): : 1723 - 1725
  • [32] Gene of the month: APOL1
    Raghubeer, Shanel
    Pillay, Tahir S.
    Matsha, Tandi Edith
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 2020, 73 (08) : 441 - 443
  • [33] APOL1 gene variants and kidney disease in whites: the cardiovascular health study
    Drury, Erika R.
    Friedman, David J.
    Pollak, Martin R.
    Ix, Joachim H.
    Kuller, Lewis H.
    Tracy, Russell P.
    Mukamal, Kenneth J.
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34 (12) : 2155 - 2156
  • [34] A Brief History of APOL1: A Gene Evolving
    Friedman, David J.
    [J]. SEMINARS IN NEPHROLOGY, 2017, 37 (06) : 508 - 513
  • [35] Ten years in: APOL1 reaches beyond the kidney
    Waitzman, Joshua S.
    Lin, Jennie
    [J]. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2019, 28 (04) : 375 - 382
  • [36] Histopathologic findings associated with APOL1 risk variants in chronic kidney disease
    Larsen, Christopher P.
    Beggs, Marjorie L.
    Saeed, Mohammad
    Ambruzs, Josephine M.
    Cossey, L. Nicholas
    Messias, Nidia C.
    Walker, Patrick D.
    Freedman, Barry I.
    [J]. MODERN PATHOLOGY, 2015, 28 (01) : 95 - 102
  • [37] Genetics of kidney failure and the evolving story of APOL1
    Friedman, David J.
    Pollak, Martin R.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (09) : 3367 - 3374
  • [38] Impact of APOL1 Genetic Variants on HIV-1 Infection and Disease Progression
    An, Ping
    Kirk, Gregory D.
    Limou, Sophie
    Binns-Roemer, Elizabeth
    Kopp, Jeffrey B.
    Winkler, Cheryl A.
    [J]. FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [39] Sodium-glucose co-transporter inhibitors for APOL1 kidney disease: A call for studies
    Afsar, Baris
    Afsar, Rengin Elsurer
    Caliskan, Yasar
    Lentine, Krista L.
    [J]. INTERNATIONAL UROLOGY AND NEPHROLOGY, 2025,
  • [40] Practical Considerations for APOL1 Genotyping in the Living Kidney Donor Evaluation
    Mena-Gutierrez, Alejandra M.
    Reeves-Daniel, Amber M.
    Jay, Colleen L.
    Freedman, Barry I.
    [J]. TRANSPLANTATION, 2020, 104 (01) : 27 - 32
12345